Clinical Trials
59 trialsNCT04633252 2026-05-27
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07288359 2026-05-27
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT06574880 2026-05-26
STARLiT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07529717 2026-05-22
CRIUS-1
AstraZeneca
Phase 1/2 Recruiting
NCT03317392 2026-05-20
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT03437941 2026-05-15
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
Phase 1/2 Terminated
NCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT07564102 2026-05-15
dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy
Mochida Medical USA, Inc.
Phase 1/2 Not yet recruiting
NCT07590934 2026-05-15
PROSPECTOR
AstraZeneca
Phase 1/2 Not yet recruiting
NCT05413850 2026-05-14
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT07285694 2026-05-14
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Arsenal Biosciences, Inc.
Phase 1/2 Recruiting
NCT04071236 2026-05-13
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04145375 2026-05-08
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Zenith Epigenetics
Phase 1/2 Enrolling by invitation
NCT07181161 2026-05-08
SEACLIFF
AstraZeneca
Phase 1/2 Recruiting
NCT07414940 2026-05-08
ACT-RESoLUTE
University College, London
Phase 1/2 Recruiting
NCT07192614 2026-05-07
ACTIVATED-4-PC
AstraZeneca
Phase 1/2 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07570966 2026-05-06
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Not yet recruiting
NCT03217747 2026-05-05
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05067140 2026-05-05
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Phase 1/2 Active not recruiting
NCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT06085664 2026-05-05
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06616155 2026-05-05
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT07567521 2026-05-05
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
C Ray Therapeutics
Phase 1/2 Not yet recruiting
NCT07567846 2026-05-05
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Genentech, Inc.
Phase 1/2 Not yet recruiting
NCT03067051 2026-05-01
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
SpectraCure AB
Phase 1/2 Recruiting
NCT04194554 2026-05-01
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT06807359 2026-05-01
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
SpectraCure AB
Phase 1/2 Recruiting
NCT07336446 2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2 Recruiting
NCT05983198 2026-04-29
SatisfACtion
Novartis
Phase 1/2 Active not recruiting
NCT07117760 2026-04-29
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Active not recruiting
NCT06785636 2026-04-24
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT06990880 2026-04-24
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06600698 2026-04-23
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
NCT07332455 2026-04-22
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
GlaxoSmithKline
Phase 1/2 Recruiting
NCT04946370 2026-04-21
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT07407283 2026-04-21
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT06615752 2026-04-15
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
Phase 1/2 Recruiting
NCT07002320 2026-04-15
ASpiRE
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT05113537 2026-04-13
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT06190899 2026-04-13
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT06085729 2026-04-02
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06395519 2026-03-27
ERADIC8
858 Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06457919 2026-03-24
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting